CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
local injection of bevacizumabdrug
Likely dose
local injection of bevacizumab 0.1mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00592176
NCT00592176Phase 2Completed
CompareCT.gov

The Effect of Bevacizumab (Avastin) on Pterygium

University of Alabama at Birmingham·interventional·Posted Jan 11, 2008·Updated Jun 4, 2014

In Brief

A Phase 2 clinical trial evaluating local injection of bevacizumab for Pterygium. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPterygium
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartAug 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.5 years ago

Interventions

local injection of bevacizumabdrug

Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.